GMHC Treatment Issues 1995 Sep 1; 9(9): 9
A new study using injectable (subcutaneous) peptide T for
HIV-associated cognitive impairment has opened at eleven
sites nationwide. This study follows a recently concluded
German study that found a trend towards improvement in some
measures of neurocognitive ability in people with less than
100 CD4 cells who were given peptide T (8.5 mg a day,
Various mechanisms of action have been attributed to peptide
T in the course of its long history (see Treatment Issues,
February 1994, pages 5-9). It supposedly helps neurocognitive
impairment by reducing brain levels of TNF-alpha, an immune
system stimulant present in high levels during HIV infection.
TNF-alpha has been implicated in at least some of the
neurologic damage that occurs in HIV-associated dementia.
This twelve-week study will compare placebo to two doses of
peptide T, 8.5 and 17.0 mg a day in at least 160 people with
HIV and evidence of HIV-related cognitive impairment.
Participants must have adequate English language skills to be
able to complete tests used in evaluating cognitive
performance. At the completion of the study, participants
will receive drug on an open label basis. For more
information, call 800/4-STUDY-T.
The sponsoring company, Peptech, also has opened a treatment
IND protocol to provide free access to peptide T for fifty
people. At present, the program is limited to one site in
Baltimore, (through Chase Brexton, call Dr. Karla Alexander,
401/837-2050). Peptech will open two more sites for the
program in the future.